Literature DB >> 16565322

RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization.

Jang-Il Han1, Ning-Na Huang, Dong-Uk Kim, John H Kehrl.   

Abstract

Chemokines bind receptors that are members of the G-protein-coupled receptor family. Chemokine receptors transduce intracellular signals by activating heterotrimeric G-proteins. Acting to limit and modulate heterotrimeric G-protein signaling is a family of proteins, termed regulator of G-protein signaling (RGS). Two of these proteins, RGS1 and RGS13, are well-expressed in germinal center B cells and many Burkitt's lymphoma cell lines. Reducing RGS13 and to a lesser extent RGS1 expression in a Burkitt's lymphoma cell line enhances responsiveness to two chemokines, CXC chemokine ligand 12 (CXCL12) and CXCL13, and reducing both mRNAs augments the responses more dramatically. The double knock-down (KD) cells respond better to restimulation with CXCL12 or CXCL13 after a primary stimulation with CXCL12 than do the control cells. The double-KD cells also exhibit a greater propensity to polarize and to develop multiple small lamellipodia. These results indicate that RGS1 and RGS13 act together to regulate chemokine receptor signaling in human germinal center B lymphocytes and provide evidence that they contribute significantly to the rapid desensitization of the signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565322     DOI: 10.1189/jlb.1105693

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  31 in total

Review 1.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  p53 negatively regulates RGS13 protein expression in immune cells.

Authors:  Shoko Iwaki; Yunbiao Lu; Zhihui Xie; Kirk M Druey
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

Review 3.  Chemoattractant receptor signaling and the control of lymphocyte migration.

Authors:  John H Kehrl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Regulation of Chemokine Signal Integration by Activator of G-Protein Signaling 4 (AGS4).

Authors:  William G Robichaux; Melissa Branham-O'Connor; Il-Young Hwang; Ali Vural; Johne H Kehrl; Joe B Blumer
Journal:  J Pharmacol Exp Ther       Date:  2017-01-06       Impact factor: 4.030

5.  Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases.

Authors:  Jae-Kyung Lee; Josephine Bou Dagher
Journal:  AAPS J       Date:  2016-02-22       Impact factor: 4.009

6.  Regulated genes in mesenchymal stem cells and gastric cancer.

Authors:  Shihori Tanabe; Kazuhiko Aoyagi; Hiroshi Yokozaki; Hiroki Sasaki
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

7.  Regulator of G protein signaling 5 restricts neutrophil chemotaxis and trafficking.

Authors:  Eunice C Chan; Chunguang Ren; Zhihui Xie; Joseph Jude; Tolga Barker; Cynthia A Koziol-White; Michelle Ma; Reynold A Panettieri; Dianqing Wu; Helene F Rosenberg; Kirk M Druey
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

Review 8.  Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.

Authors:  Katherine E Squires; Carolina Montañez-Miranda; Rushika R Pandya; Matthew P Torres; John R Hepler
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

9.  Variations in Gnai2 and Rgs1 expression affect chemokine receptor signaling and the organization of secondary lymphoid organs.

Authors:  I Y Hwang; C Park; K A Harrision; N N Huang; J H Kehrl
Journal:  Genes Immun       Date:  2010-05-27       Impact factor: 2.676

Review 10.  R4 RGS proteins: regulation of G-protein signaling and beyond.

Authors:  Geetanjali Bansal; Kirk M Druey; Zhihui Xie
Journal:  Pharmacol Ther       Date:  2007-10-05       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.